Kairos Pharma Ltd (AMEX: KAPA) kicked off on Friday, up 7.14% from the previous trading day, before settling in for the closing price of $1.26. Over the past 52 weeks, KAPA has traded in a range of $0.40-$4.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -23.37% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 0.00%. With a float of $8.77 million, this company’s outstanding shares have now reached $17.74 million.
Kairos Pharma Ltd (KAPA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kairos Pharma Ltd is 57.73%, while institutional ownership is 5.32%. The most recent insider transaction that took place on Nov 25 ’24, was worth 318. In this transaction VP of Research and Development of this company bought 200 shares at a rate of $1.59, taking the stock ownership to the 133,057 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Chief Financial Officer bought 2,500 for $1.50, making the entire transaction worth $3,750. This insider now owns 60,796 shares in total.
Kairos Pharma Ltd (KAPA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.1 earnings per share (EPS), lower than consensus estimate (set at -0.02) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -29.25% during the next five years compared to -23.37% drop over the previous five years of trading.
Kairos Pharma Ltd (AMEX: KAPA) Trading Performance Indicators
Take a look at Kairos Pharma Ltd’s (KAPA) current performance indicators. Last quarter, stock had a quick ratio of 7.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Kairos Pharma Ltd (KAPA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.66 million. That was inferior than the volume of 2.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.88%.
During the past 100 days, Kairos Pharma Ltd’s (KAPA) raw stochastic average was set at 66.90%, which indicates a significant decrease from 94.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1159 in the past 14 days, which was higher than the 0.0916 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9384, while its 200-day Moving Average is $1.1077. However, in the short run, Kairos Pharma Ltd’s stock first resistance to watch stands at $1.3933. Second resistance stands at $1.4367. The third major resistance level sits at $1.5033. If the price goes on to break the first support level at $1.2833, it is likely to go to the next support level at $1.2167. Assuming the price breaks the second support level, the third support level stands at $1.1733.
Kairos Pharma Ltd (AMEX: KAPA) Key Stats
The company with the Market Capitalisation of 28.00 million has total of 20,744K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -2,600 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -1,420 K.
